AMG 827 in Subjects With Psoriatic Arthritis

Inclusion Criteria:

Subject has had a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis (CASPAR) criteria) for at least 6 months
Subject has ≥ 3 tender and ≥ 3 swollen joints

Exclusion Criteria:

Subject has an active infection or history of infections (systemic anti-infectives were used within 28 days; requiring hospitalization or intravenous anti-infectives within 8 weeks; recurrent or chronic)
Significant concurrent medical conditions
Pregnant or breast feeding
Significant Laboratory abnormalities
Use of sulfasalazine, hydroxychloroquine, systemically administered calcineurin inhibitors, azathioprine, parenteral corticosteroids including intramuscular or intraarticular administration, or live vaccines within 28 days
Use of anti-TNF therapy within 2 months
Use of an anti-interleukin (IL)12/IL-23 drug or other experimental or commercially available biologic therapies for psoriasis and/or psoriatic arthritis within 3 months
Prior use of rituximab
Prior use of anti-IL-17 biologic therapy, including AMG 827